Article
NLRP3 promoter methylation as a predictive biomarker for glucocorticoid response in patients with inflammatory bowel disease
17 Jan 2025
Abstract excerpt
Glucocorticoids are used for inflammatory bowel disease (IBD) therapy; however nearly 50 % of IBD patients exhibit resistance or dependence. This study evaluates the relationship between methylation level at two CpG sites (cg21991396 and cg00448525) within NLRP3 promoter and glucocorticoid response of 94 IBD pediatrics (39 with Crohn's disease (40.4 %)) and 47 IBD adults (26 with Crohn's disease (55.3 %))....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
